John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital, Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Stanifer, John W., Sean D. Pokorney, Glenn M. Chertow, Stefan H. Hohnloser, Daniel M. Wojdyla, Samira Garonzik, Wonkyung Byon, et al. “Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.” Circulation 141, no. 17 (April 28, 2020): 1384–92. https://doi.org/10.1161/CIRCULATIONAHA.119.044059.

PMID
32160801
Full Text

Inagaki, Nobuya, Wenying Yang, Hirotaka Watada, Linong Ji, Sven Schnaidt, Egon Pfarr, Tomoo Okamura, et al. “Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.” Diabetol Int 11, no. 2 (April 2020): 129–41. https://doi.org/10.1007/s13340-019-00412-x.

PMID
32206483
Full Text

Gelijns, Annetine C., Alan J. Moskowitz, Patrick T. O’Gara, Gennaro Giustino, Michael J. Mack, Donna M. Mancini, Emilia Bagiella, et al. “Transcatheter mitral valve repair for functional mitral regurgitation: Evaluating the evidence.” J Thorac Cardiovasc Surg, March 21, 2020. https://doi.org/10.1016/j.jtcvs.2020.02.132.

PMID
32359794
Full Text

Zeitouni, Michel, Anna Giczewska, Renato D. Lopes, Daniel M. Wojdyla, Christina Christersson, Agneta Siegbahn, Raffaele De Caterina, et al. “Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial.” J Am Coll Cardiol 75, no. 10 (March 17, 2020): 1145–55. https://doi.org/10.1016/j.jacc.2019.12.060.

PMID
32164888
Full Text

Lopes, Renato D., Sergio Leonardi, Daniel M. Wojdyla, Amit N. Vora, Laine Thomas, Robert F. Storey, Dragos Vinereanu, et al. “Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.” Circulation 141, no. 9 (March 3, 2020): 781–83. https://doi.org/10.1161/CIRCULATIONAHA.119.044584.

PMID
31707833
Full Text

Bahit, M Cecilia, Christopher B. Granger, John H. Alexander, Hillary Mulder, Daniel M. Wojdyla, Michael Hanna, Shinya Goto, et al. “Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial.” Int J Cardiol 302 (March 1, 2020): 53–58. https://doi.org/10.1016/j.ijcard.2019.12.060.

PMID
31932116
Full Text

Garcia, David A., Deborah A. Fisher, Hillary Mulder, Lisa Wruck, Raffele De Caterina, Sigrun Halvorsen, Christopher B. Granger, et al. “Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.” Am Heart J 221 (March 2020): 1–8. https://doi.org/10.1016/j.ahj.2019.10.013.

PMID
31896036
Full Text

Lopes, Renato D., Hwanhee Hong, Ralf E. Harskamp, Deepak L. Bhatt, Roxana Mehran, Christopher P. Cannon, Christopher B. Granger, et al. “Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.” Jama Cardiol, February 26, 2020. https://doi.org/10.1001/jamacardio.2019.6175.

PMID
32101251
Full Text

Lopes, Renato D., Pedro G. M. de Barros E Silva, Lucas Petri Damiani, Renato Hideo Nakagawa Santos, John H. Alexander, Christopher B. Granger, and Otavio Berwanger. “Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCI.” Jama 323, no. 8 (February 25, 2020): 787–89. https://doi.org/10.1001/jama.2020.0118.

PMID
32096839
Full Text

Marquis-Gravel, Guillaume, Zhen Huang, Steven L. Zelenkofske, A Michael Lincoff, Roxana Mehran, P Gabriel Steg, Christoph Bode, John H. Alexander, and Thomas J. Povsic. “Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial.” Am Heart J 223 (February 24, 2020): 84–86. https://doi.org/10.1016/j.ahj.2020.02.013.

PMID
32199152
Full Text

Pages